Synthetic IgM Antibody Controls for Measles, Mumps, and Rubella Assays
This grant opportunity seeks Phase I SBIR proposals (but not Fast-track or Phase I clinical trials) to address the public health challenges posed by measles, rubella, and mumps infections. There is funding for one anticipated award. For Phase I, the budget is up to $243,500 for a duration of up to 6 months. If successful, Phase II could provide further funding up to $2,045,816 for up to two ad…
Phase I SBIR proposals will be accepted.\nFast-track proposals will not be accepted.\nPhase I clinical trials will not be accepted.\n\nNumber of anticipated awards: 1\n\nBudget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $2,045,816 and a Phase II duration of up to…
Funding Source
Dates
Documents
Secure Grant Funding 10x Faster
Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.
Already have an account? Sign In
Trusted by 500+ Happy Customers